Brief: CSPC Pharmaceutical Says Paclitaxel For Injection (Albumin-Bound) (Ii) Patented In China, US, And Europe
15/06/2026 15:00
BRIEF-CSPC Pharmaceutical Says Paclitaxel For Injection (Albumin-Bound) (Ii) Patented In China, US, And Europe June 15 (Reuters) - CSPC Pharmaceutical Group Ltd 1093.HK:
PACLITAXEL FOR INJECTION (ALBUMIN-BOUND) (II) PATENTED IN CHINA, US, AND EUROPE
Further company coverage: 1093.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines